We are live on ! Find out more
CRDL

Cardiol Therapeutics
CRDL

38 hedge funds and large institutions have $7.44M invested in Cardiol Therapeutics in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

7,650% more call options, than puts

Call options by funds: $155K | Put options by funds: $2K

56% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 9

0.28% more ownership

Funds ownership: 9.18% → 9.46% (+0.28%)

12% less funds holding

Funds holding: 43 → 38 (-5)

23% less capital invested

Capital invested by funds: $9.6M → $7.44M (-$2.16M)

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

Holders
38
Holders Change
-5
Holders Change %
-11.63%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
14
Reduced
9
Closed
9
Calls
$155K
Puts
$2K
Net Calls
+$153K
Net Calls Change
-$30K

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$323K
2
AI
AdvisorShares Investments
Maryland
+$123K
3
TC
Tejara Capital
United Kingdom
+$97.7K
4
UBS AM
UBS AM
Illinois
+$67.5K
5
LSA
Lion Street Advisors
Texas
+$32K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$178K
2
PAM
PVG Asset Management
Colorado
-$61.3K
3
Citadel Advisors
Citadel Advisors
Florida
-$46.8K
4
VF
Virtu Financial
New York
-$39.3K
5
LPL Financial
LPL Financial
California
-$23.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
EPIM
26
Evelyn Partners Investment Management
$9.52K – – –
Group One Trading
27
Group One Trading
Illinois
$8.19K +$3.85K +3,139 +59%
National Bank of Canada
28
National Bank of Canada
Quebec, Canada
$8.15K +$3.29K +2,678 +46%
TWC
29
TD Waterhouse Canada
Ontario, Canada
$6.43K – – –
Osaic Holdings
30
Osaic Holdings
Arizona
$4.1K +$669 +545 +15%
VNA
31
Valley National Advisers
Pennsylvania
$4K – – –
HFM
32
Hartford Financial Management
Connecticut
$3.88K – – –
SC
33
SouthState Corp
Florida
$970 – – –
SS
34
SBI Securities
Japan
$461 +$246 +200 +73%
PPA
35
Painted Porch Advisors
California
$143 -$433 -353 -71%
TRCT
36
Tower Research Capital (TRC)
New York
$114 +$145 +118 New
SHIM
37
Stone House Investment Management
Pennsylvania
$48 +$61 +50 New
Wells Fargo
38
Wells Fargo
California
$24 -$2.42K -1,975 -99%
Citadel Advisors
39
Citadel Advisors
Florida
– -$46.8K -38,110 Closed
LPL Financial
40
LPL Financial
California
– -$23.4K -18,310 Closed
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
– -$22.2K -17,364 Closed
Wealth Enhancement Advisory Services
42
Wealth Enhancement Advisory Services
Minnesota
– -$17.3K -13,538 Closed
Marshall Wace
43
Marshall Wace
United Kingdom
– -$16.9K -13,193 Closed
NWWA
44
New Wave Wealth Advisors
Arkansas
– -$1.28K -1,000 Closed
WWA
45
Wingate Wealth Advisors
Massachusetts
– -$109 -85 Closed
MCM
46
MAI Capital Management
Ohio
– -$32 -25 Closed
Toronto Dominion Bank
47
Toronto Dominion Bank
Ontario, Canada
– -$1 -1 Closed
1
2

CRDL Hedge Fund Activity: Q1 2025 in Review

38 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q1 2025, worth a combined $7.44M — down 23% from $9.6M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of CRDL and 4 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 14 added.

The largest buyer was UBS Group, adding an estimated $323K. The largest seller was Morgan Stanley, cutting an estimated $178K.

  • 38 institutional investors held Cardiol Therapeutics (CRDL) as of Q1 2025, down from 43 in Q4 2024.
  • Funds reported $7.44M of Cardiol Therapeutics stock for Q1 2025, down 23% quarter-over-quarter.
  • 4 funds opened new Cardiol Therapeutics positions in Q1 2025 and 9 closed out, a net change of -5 holders.
  • The largest Cardiol Therapeutics buyer in Q1 2025 was UBS Group, an estimated $323K added.
  • The largest Cardiol Therapeutics seller in Q1 2025 was Morgan Stanley, an estimated $178K sold.

Based on aggregated 13F filings for Q1 2025.